Severe Sepsis Clinical Trial
Official title:
Randomized Multicentre Prospective Study of Procalcitonin-guided Treatment on Antibiotic Use and Outcome in Severe Sepsis ICU Patients Without Obvious Infection
A recent study has demonstrated that in low respiratory infections, a strategy using
prescription of antibiotics based on the pro-calcitonin level allows decreasing recourse to
antibiotics by 47% without prognostic modification.
The aim is to evaluate the impact on antibiotics consumption of an algorithm using
procalcitonin level in patients exhibiting severe sepsis symptomatology but without clearly
identified hosted germs or infectious centre.
This multicenter study is a randomized prospective open study involving 9 ICU departments in
France, comparing two strategies on antibiotherapy treatment period one based on
procalcitonin level(experimental group) the other on physician's appreciation(control group)
140 adult patients should be included with a severe sepsis symptomatology, whose infectious
etiology has not been proven. The main non-inclusion criterium is: the presence of a
pathogen agent or infectious centre clearly identified.
The primary outcome is the rate of patients undergoing antibiotic treatment at D5.
Secondary outcomes: duration of the antibiotic treatment, mortality rate and duration in
stay in intensive care ward and evolution of the SOFA score between D0, D3 and D5.
Duration of patient enrollment is 30 days.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
| Completed |
NCT02539147 -
Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis
|
N/A | |
| Completed |
NCT01929772 -
German Lactat Clearance in Severe Sepsis
|
N/A | |
| Completed |
NCT01932814 -
Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?
|
N/A | |
| Completed |
NCT01449721 -
Preemptive Resuscitation for Eradication of Septic Shock
|
N/A | |
| Active, not recruiting |
NCT01162109 -
Zinc Therapy in Critical Illness
|
Phase 1 | |
| Not yet recruiting |
NCT01211899 -
4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock
|
N/A | |
| Completed |
NCT00934011 -
Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections
|
N/A | |
| Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
| Completed |
NCT00463645 -
Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients
|
N/A | |
| Completed |
NCT02361528 -
GM-CSF to Decrease ICU Acquired Infections
|
Phase 3 | |
| Completed |
NCT02734550 -
(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis
|
N/A | |
| Completed |
NCT02973243 -
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
|
N/A | |
| Terminated |
NCT03895853 -
Early Metabolic Resuscitation for Septic Shock
|
Phase 2 | |
| Completed |
NCT01945983 -
Early Use of Norepinephrine in Septic Shock Resuscitation
|
N/A | |
| Completed |
NCT01598831 -
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
|
Phase 3 | |
| Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A |